{
  "id": 21032608,
  "title": "Bayer Roundup Settlement: Who Qualifies and How Much Could They Get?",
  "url": "https://urgent.news/2026/11/21/bayer-roundup-settlement-who-qualifies-and-how-much-could-they-get",
  "topic": "culture",
  "section": "Culture",
  "published": "2026-11-21T10:37:12.000Z",
  "source": {
    "name": "Newsweek",
    "slug": "newsweek",
    "url": "https://www.newsweek.com/bayer-roundup-settlement-who-qualifies-how-much-12751015"
  },
  "original_language": "en",
  "account": "A Missouri judge approved Bayer's $7.25 billion settlement of lawsuits claiming its Roundup weedkiller causes cancer. The June U.S. Supreme Court ruling made it harder to sue Monsanto, which owns Roundup, over the lack of a cancer warning on the product. Eligible claimants must have been diagnosed with non-Hodgkin lymphoma or receive a diagnosis within the program's 16-year coverage period, starting February 17, 2026. Timothy Boyer, the judge, deemed the agreement \"fair, reasonable, and adequate.\" Monsanto denies liability and insists that glyphosate does not cause cancer. The settlement cover U.S. residents exposed to Roundup before the cutoff date, who developed non-Hodgkin lymphoma or receive a diagnosis during the program. Compensation depends on the type of exposure (occupational or residential) and various factors, including age, disease aggressiveness, and quality of exposure evidence. Eligible claimants must provide medical records, exposure proof, identification, and residency evidence. The administrator, BrownGreer PLC, will process claims through a secure portal. The settlement does not provide a direct path for those who previously settled with Monsanto, as some prior agreements may affect payout calculations.",
  "summary": "Awards may reach $165,000, but age, diagnosis and exposure history will help determine how much each qualifying claimant receives.",
  "key_points": [
    "Missouri judge approves $7.25B Bayer Roundup settlement",
    "Eligible claimants must have non-Hodgkin lymphoma diagnosis",
    "Compensation varies by exposure type and evidence quality"
  ],
  "editors_take": "This massive payout offers a final resolution for non-Hodgkin lymphoma claimants while reinforcing the legal hurdles established by recent Supreme Court rulings regarding product liability and cancer warnings.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}